Hamada N, Okamoto Y, Yamakawa J, Ohno M, Noh J, Yano T, Shibata M, Ito K, Morii H
Thyroid Study Unit, Sumire Hospital, Osaka Social Welfare Foundation, Japan.
Osaka City Med J. 1993 Jun;39(1):57-66.
One way to locate antigenic determinants in thyroid peroxidase (TPO) is to evaluate the binding of chemically synthesized peptides to autoantibodies. A major epitope of TPO involved in thyroid autoimmunity has been reported to be at residues 590 to 675. Therefore, we synthesized three peptides (P1, residues 603-610; P2, 615-630; and P3, 654-665) in the most antigenic part of this range, as judged by antigenicity analysis, and measured their antigenicity by enzyme-linked immunosorbent assay (ELISA). Amino groups protected with fluorenyl-methoxycarbonyl were used in the synthesis. Sera from 42 untreated patients with Hashimoto's disease and 30 untreated patients with Graves' disease were tested for binding with each peptide. In addition, 6 sera with antibodies against denatured and reduced microsomal antigen were tested. Sera obtained from 22 normal subjects were used as a control. Binding of sera from the patients with autoimmune thyroid disease to the synthetic peptides was weak, about 1% of binding to thyroid microsomes prepared from Graves' thyroid. However, the ELISA index of a mixture of P1, P2, and P3 was significantly higher in the patients with Hashimoto's disease than in the healthy subjects. For both P2 and P3, the ELISA index of the sera with antibodies against denatured and reduced TPO was higher than that of the sera from normal subjects. These results suggested 1) that the antigenic epitopes of TPO recognized by autoantibodies may be conformational and discontinuous, and 2) that antibodies against these linear portions of TPO may exist in patients with Hashimoto's disease.
确定甲状腺过氧化物酶(TPO)中抗原决定簇的一种方法是评估化学合成肽与自身抗体的结合情况。据报道,参与甲状腺自身免疫的TPO主要表位位于590至675位残基处。因此,根据抗原性分析,我们在该范围最具抗原性的部分合成了三种肽(P1,603 - 610位残基;P2,615 - 630位残基;P3,654 - 665位残基),并通过酶联免疫吸附测定(ELISA)测量它们的抗原性。合成过程中使用了用芴甲氧羰基保护的氨基。对42例未经治疗的桥本氏病患者和30例未经治疗的格雷夫斯病患者的血清进行了与每种肽结合情况的检测。此外,还检测了6份含有抗变性和还原微粒体抗原抗体的血清。将22名正常受试者的血清用作对照。自身免疫性甲状腺疾病患者的血清与合成肽的结合较弱,约为与从格雷夫斯病甲状腺制备的甲状腺微粒体结合的1%。然而,桥本氏病患者中P1、P2和P3混合物的ELISA指数显著高于健康受试者。对于P2和P3,含有抗变性和还原TPO抗体的血清的ELISA指数均高于正常受试者的血清。这些结果表明:1)自身抗体识别的TPO抗原表位可能是构象性和不连续的;2)桥本氏病患者体内可能存在针对TPO这些线性部分的抗体。